Celltrion applied to the FDA for a license to sell 'Lamsima' which is the world's first antibody biosimilar
On August 11, Celltrion announced that they applied to the FDA for a license to sell 'Remsima' which is the world's first antibody biosimilar on 8th last month.
This is the first time the United States permit the application of biotechnology to the antibody biosimilar, and it was the second case...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
